Cargando…
Specific Therapy for T2 Asthma
Asthma is a disease with high incidence and prevalence, and its severe form accounts for approximately 10% of asthmatics. Over the last decade, the increasing knowledge of the mechanisms underlying the disease allowed the development of biological drugs capable of sufficiently controlling symptoms a...
Autores principales: | Bagnasco, Diego, Testino, Elisa, Nicola, Stefania, Melissari, Laura, Russo, Maria, Canevari, Rikki Frank, Brussino, Luisa, Passalacqua, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031027/ https://www.ncbi.nlm.nih.gov/pubmed/35455709 http://dx.doi.org/10.3390/jpm12040593 |
Ejemplares similares
-
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023) -
Severe asthma: One disease and multiple definitions
por: Bagnasco, Diego, et al.
Publicado: (2021) -
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021) -
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
por: Bagnasco, Diego, et al.
Publicado: (2018) -
Critical evaluation of asthma biomarkers in clinical practice
por: Guida, Giuseppe, et al.
Publicado: (2022)